The incidence of M. tuberculosis resistance to linezolid and bedaquiline in patients for the period 2011-2022
https://doi.org/10.54921/2413-0346-2024-12-3-20-25
Abstract
The objective. To analyze the incidence of linezolid- and bedaquiline-resistant strains of M. tuberculosis from smear-positive TB patients in 2011–2022.
Subjects and Methods. A total of 3637 clinical strains were obtained from patients undergoing treatment in the CTRI in 2011-2022. Drug susceptibility for linezolid and bedaquiline were determined using Bactec MGIT 960 (Becton Dickinson, USA) with a critical concentration of 1 mg/L.
Results. 101 patients with linezolid- and bedaquiline-resistant strains were detected. The incidence of linezolid-resistance increases from 0,2% in 2011 to 5,5% in 2022 (p<0,05). The incidence of bedaquiline-resistance also increases from 1,4% in 2018 to 12,2% in 2022 (p<0,05).
Conclusion. Resistance to linezolid and bedaquiline is increasing for the period 2011-2022. Molecular methods for linezolid and bedaquiline resistance detection are urgently needed.
About the Authors
V. V. Algazina
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Moscow
T. G. Smirnova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Moscow
V. V. Romanov
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Moscow
A. E. Ergeshov
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Moscow
References
1. Васильева И.А., Тестов В.В., Стерликов С.А. Эпидемическая ситуация по туберкулезу в годы пандемии COVID-19 – 2020-2021 гг. // Туберкулез и болезни легких. – 2022. – Т. 100. - № 3. – С. 6-12. http://doi.org/10.21292/2075-1 230-2022-100-3-6-12
2. Захаров А.В., Тихонов А.М., Полякова А.С. и др. Клинические аспекты и эффективность комплексного лечения туберкулеза легких с широкой лекарственной устойчивостью возбудителя у больных разных регистрационных групп // Вестн. Центрального НИИ туберкулеза. – 2022. – № 1. – С. 54-68.
3. Клинические рекомендации «Туберкулез у взрослых». – 2022
4. Стерликов С.А., Васильева И.А., Михайлова Ю.В., Кудрина В.Г., Тестов В.В. Новое определение и эпидемиология туберкулеза с широкой лекарственной устойчивостью микобактерий туберкулеза в 2020 году // Туберкулез и болезни легких. – 2023. – Т. 101. - № 2. – С. 14-19. https://doi.org/10.58838/2075-1230-2023-101-2-14-19
5. Филиппов А.В. Эффективность и безопасность режимов химиотерапии туберкулеза, включающих бедаквилин и антибактериальные препараты широкого спектра действия: Автореф. дисс. … канд. мед. наук. – М., 2022.
6. Agyeman A.A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis // Ann. Clin. Microbiol. Antimicrob. – 2016. – Vol. 22, № 15(1). – P. 41. doi: 10.1186/s12941-016-0156-y. PMID: 27334498; PMCID: PMC4917997.)
7. Goulooze S.C., Cohen A.F., Rissmann R. Bedaquiline // Br. J. Clin. Pharmacol. – 2015. – Vol. 80, № 2. – P. 182-184. doi: 10.1111/bcp.12613. Epub 2015 Jul 2. PMID: 25702772; PMCID: PMC4541965.
8. Kadura S., King N., Nakhoul M., Zhu H., Theron G., Köser C.U., Farhat M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid // J. Antimicrob. Chemother. – 2020. – Vol. 75, № 8. – P. 2031-2043. doi: 10.1093/jac/dkaa136. PMID: 32361756; PMCID: PMC7825472.
9. Kloss P., Xiong L., Shinabarger D.L., Mankin A.S. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center // J. Mol. Biol. – 1999. – Vol. 294, № 1. – P. 93-101. doi: 10.1006/jmbi.1999.3247. PMID: 10556031.
10. Richter E., Rüsch-Gerdes S., Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis // Antimicrob. Agents Chemother. – 2007. – Vol. 51, № 4. – P. 1534-1536. doi: 10.1128/AAC.01113-06. Epub 2007 Jan 22. PMID: 17242139; PMCID: PMC1855508.
11. Siddiqi S.H., Rusch-Gerdes S. MGIT Procedure Manual for BACTEC MGIT 960 TB System. – 2006. – C. 14-18.
12. Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., Ouellette M., Outterson K., Patel J., Cavaleri M., Cox E.M., Houchens C.R., Grayson M.L., Hansen P., Singh N., Theuretzbacher U., Magrini N. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis // Lancet Infect. Dis. – 2018. – Vol. 18, № 3. – P. 318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. PMID: 29276051.
13. Wilson D.N., Schluenzen F., Harms J.M., Starosta A.L., Connell S.R., Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning // Proc. Natl. Acad. Sci. USA. – 2008. – Vol. 105, № 36. – P. 13339-13344. doi: 10.1073/pnas.0804276105. Epub 2008 Aug 29. PMID: 18757750; PMCID: PMC2533191.
14. World Health Organization. Global tuberculosis report. 2020. – WHO, 2020.
15. World Health Organization. Global tuberculosis report. 2021. – WHO, 2021
Review
For citations:
Algazina V.V., Smirnova T.G., Romanov V.V., Ergeshov A.E. The incidence of M. tuberculosis resistance to linezolid and bedaquiline in patients for the period 2011-2022. Tuberculosis and socially significant diseases. 2024;12(3):20-25. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-3-20-25
Views:
210
Email this article 